Silibinin Lipoic Acid Ester Synthesis for Hepatoprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatoprotective drugs for liver injury, such as those caused by alcohol, drugs, and viruses, have unsatisfactory efficacy and potential toxic side effects, limiting their clinical application.
Innovation Solution
A silibinin lipoic acid ester is synthesized by reacting silibinin with lipoic acid using specific solvents and catalysts, followed by purification, to produce a compound with excellent hepatoprotective and antioxidant activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hepatoprotective drugs are used, then liver injury treatment is provided, but efficacy is unsatisfactory and toxic side effects occur
Solution Approach 1:
The patent synthesizes a composite molecule by conjugating silibinin (from milk thistle) with lipoic acid through ester bond formation. This creates a new hepatoprotective compound that combines the hepatoprotective properties of silibinin with the antioxidant and anti-inflammatory effects of lipoic acid, thereby improving efficacy while reducing toxicity through the synergistic action of both components
Solution Approach 2:
The patent modifies the chemical structure of silibinin by introducing a lipoic acid moiety through controlled esterification reactions. This structural parameter change enhances the drug's pharmacological properties, including improved liver protection efficacy and reduced hepatotoxicity, while maintaining solubility and bioavailability through careful selection of ester linkage positions
2Reliability
If silibinin and lipoic acid are reacted to form the ester, then hepatoprotective activity is improved, but reaction conditions and purification complexity increase
Solution Approach 1:
The patent employs carbodiimide coupling agents (such as EDC or DCC) as intermediaries to facilitate the esterification reaction between silibinin and lipoic acid. These intermediaries activate the carboxyl group of lipoic acid, enabling efficient nucleophilic attack by the hydroxyl group of silibinin, thereby simplifying the reaction conditions and improving yield while reducing side reactions
Solution Approach 2:
The patent utilizes silica gel column chromatography with standardized eluent systems (petroleum ether-ethyl acetate gradients) to purify the synthesized ester. This copying of established purification methodologies allows for efficient separation of the target compound from reaction byproducts and unreacted starting materials, simplifying the overall process despite the complexity of the molecular transformation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silibinin lipoic acid ester demonstrates significant liver protective and antioxidant effects, offering a new and effective hepatoprotective product with potential for improved medical treatment of liver diseases.
Implementation Method 1
adding an organic solvent and a catalyst under nitrogen atmosphere to obtain a reaction mixture; the catalyst is EDC
Implementation Method 2
heating the reaction mixture at 50-85° C. for 1-4 hours
Implementation Method 3
concentrating the reaction mixture under reduced pressured to give a crude product
Implementation Method 4
purifying the crude product on a silica gel column with petroleum ether and ethyl acetate as an eluent
Implementation Method 5
adding the compound of formula (III) to the reactor to form a reaction mixture; the ionic liquid is 1-butyl-3-methylimidazolium tetrafluoroborate ([BMIM][BF4])
Implementation Method 6
heating the reaction mixture at 25-50° C. for 5-10 hours
Implementation Method 7
purifying the crude product by recrystallization in methanol to obtain the compound of formula (I)
Data Source
AI summary
A compound having the formula (I):is disclosed. A method of preparing the compound of formula (I) is also disclosed.